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Mutant prevention concentration (MPC) has been proposed as a new measure of antibiotic potency by which
the ability to restrict selection of resistant mutants is evaluated. To determine whether MPC provides potency
information unavailable from the more customary measurement of the MIC, 18 fluoroquinolones were exam-
ined for their ability to block the growth of Mycobacterium smegmatis and to select resistant mutants from
wild-type populations. Both MPC and MIC were affected by changes in the moiety at the fluoroquinolone C-8
position and in alkyl groups attached to the C-7 piperazinyl ring. When eight resistant mutants, altered in the
gyrase A protein, were tested with fluoroquinolones having either a methoxy or a hydrogen at the C-8 position,
the MIC for the most resistant mutant correlated better with the MPC than did the MIC for wild-type cells.
For C-8-fluorine derivatives, which were generally less active than the C-8-methoxy compounds but which were
more active than C-8-hydrogen derivatives, the MICs for both the mutant and the wild type correlated well with
the MPCs. Thus, measurement of the MICs for wild-type cells can reflect the ability of a quinolone to restrict
the selection of resistance, but often it does not. With the present series of compounds, the most potent
contained a C-8-methoxy and a small group attached to the C-7 ring.
To develop more effective antituberculosis agents, we have
been studying the fluoroquinolones. These compounds, which
act by trapping gyrase on DNA, are generally used only as
second-line therapeutics because resistance mutations in
Mycobacterium tuberculosis often render them ineffective.
For example, in the early 1990s a strain of M. tuberculosis
resistant to isoniazid, rifampin, streptomycin, and ethambutol
spread among immunocompromised persons in New York City
(1). Patients were treated with the fluoroquinolone ciproflox-
acin, and within a few months some were found harboring
strains of M. tuberculosis that were resistant to fluoroquinolo-
nes as well as to the four other agents (11). When we examined
these strains, we noticed that some fluoroquinolones (e.g.,
sparfloxacin) were more effective than others (e.g., ciprofloxa-
cin) at blocking the growth of resistant mutants after the data
were normalized to the results obtained with wild-type cells
(5, 12). This observation led to the idea that some quinolones
might be better than others at trapping resistant gyrase in
mycobacteria. Subsequent work showed that compounds with
a methoxy group attached to the C-8 position (C-8-OMe) were
particularly effective against resistant mutants (5, 13).
While examining the effects of C-8-OMe groups we observed
a complex relationship between the recovery of resistant mu-
tants and the fluoroquinolone concentration (6). Increases in
fluoroquinolone concentration cause the fraction of cells that
form colonies on quinolone-containing agar to drop sharply to
a plateau and then drop sharply a second time. We proposed
that the plateau is due to the presence of first-step, resistant
mutants in the population. If this were true, the second drop in
mutant recovery should occur when the MIC for these mutants
is approached: once the growth of first-step mutants is blocked,
no mutant should be recovered at the cell amounts used be-
cause a rare, double mutation would be required to overcome
the quinolone effect. The minimal quinolone concentration
that allows no mutant recovery when more than 1010 cells are
applied to drug-containing agar was defined as the mutant
prevention concentration (MPC). If relevant concentrations of
an antibiotic in tissue can be maintained above the MPC,
selection of resistant mutants should be severely restricted.
MPC has been measured for only a few fluoroquinolones;
consequently, structure-activity relationships are still poorly
defined. In the present work we determined the MICs and
MPCs for Mycobacterium smegmatis of fluoroquinolones that
differed in moieties attached to the C-8 position and to the C-7
piperazinyl ring. C-8 substituents influenced the effect that
C-7-ring alkyl groups have on fluoroquinolone MICs and
MPCs. When resistant gyrA (gyrase) mutants were examined,
fluoroquinolone susceptibility varied with drug structure in a
way that allowed inferences about quinolone binding to
gyrase. Data obtained with the mutants also revealed that
the MPC often correlates better with the MIC for the most
resistant first-step mutant than with the MIC for wild-type
cells, consistent with the two-mutation explanation for MPC.
Collectively, these data show that the MPCs for and the sus-
ceptibilities of resistant mutants can be used to discriminate
among closely related fluoroquinolones.
MATERIALS AND METHODS
Bacterial strains and growth. The relevant features of M. smegmatis mc2155
and its gyrA mutants are listed in Table 1. The cells were grown as liquid cultures
in Middlebrook 7H9 medium containing 10% albumin dextrose complex and
0.05% Tween 80 (8). Colonies were grown on Middlebrook 7H10 agar plates
containing a fluoroquinolone. The incubation temperature for growth was 37°C.
The MIC was determined graphically from log-log plots of the fluoroquino-
lone concentration on agar plates versus the fraction of CFU recovered, and it
was defined as the concentration required to inhibit colony formation by 99%
(MIC99) after incubation for 3 days. Cultures contained about 5 3 108 CFU per
ml prior to plating. For these determinations, fluoroquinolone concentration
increments differed by 0.01 mg/ml for wild-type cells and by 0.1 or 0.5 mg/ml for
resistant mutants, depending on the compound and the mutant. To assay the
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selection of fluoroquinolone-resistant mutants, M. smegmatis was grown to the
stationary phase (350 Klett units), harvested by centrifugation (6,000 3 g for 15
min), and resuspended in the same volume of fresh growth medium. Incubation
was continued until the turbidity of the culture reached 400 to 450 Klett units,
and the culture was again concentrated by centrifugation. The cells were resus-
pended to about 109 CFU per ml in growth medium and were then applied at
various volumes and concentrations to fluoroquinolone-containing 7H10 agar at
a maximum of 2 3 109 CFU per 100-mm-diameter agar plate. The plates were
allowed to dry in a biosafety cabinet for about 30 min at room temperature,
sealed with electrical tape to minimize evaporation, and inverted for incubation
at 37°C for 3 to 7 days. After the colonies were counted, they were confirmed to
be composed of resistant mutants by regrowth on fluoroquinolone-containing
agar.
Fluoroquinolones. Several sets of fluoroquinolones were provided by Parke-
Davis Pharmaceutical Company, Ann Arbor, Mich. (for structures, see Fig. 1).
PD135432 has the same structure as AM1155 (gatifloxacin). Ciprofloxacin was
obtained from Miles Laboratories (West Haven, Conn.). The fluoroquinolones
(10 mg) were dissolved in 0.1 ml of 1 N NaOH (1/10 of the final volume), and
then sterile water was added to give a final concentration of 10 mg/ml. This stock
solution was divided into 50-ml aliquots and was stored at 280°C. Dilution series
were prepared with autoclaved water. Solutions were occasionally stored at
220°C for several weeks.
RESULTS AND DISCUSSION
Effects of C-8- and C-7-ring substituents on inhibition of
wild-type growth by fluoroquinolones. The bacteriostatic ef-
fects of substituents attached to the C-8 position and to the C-7
piperazinyl ring of N-1-cyclopropyl fluoroquinolones were ex-
amined by measuring the MIC99 for wild-type M. smegmatis.
Three sets of compounds differing at the C-8 position (C-8-H,
C-8-OMe, and C-8-F) were compared; within each set, the
compounds differed in substituents attached to the C-7 pipera-
zinyl ring (Fig. 1). With the C-8-H series, optimal activity was
observed when two methyl groups were attached to the C-7
ring (Table 2, strain KD1163), as reported previously for My-
cobacterium avium (9). For the C-8-OMe compounds, several
C-7-ring substituents (dimethyl, monomethyl, N-ethyl, and
C-39-ethyl) improved the bacteriostatic activity by three- to
fourfold, while the N-isopropyl substituent had no effect (Table
2, strain KD1163). Each member of the C-8-OMe set had a
lower MIC99 than its counterpart in the C-8-H set. The activity
of the most potent C-8-F compound, in terms of absolute
MIC99, was in the same range as that of the most active C-8-
OMe compounds. However, the C-8-F series exhibited a pat-
tern different from that seen with the two other sets in that the
compound lacking a C-7-ring alkyl was quite active. As the size
of the alkyl groups increased beyond the monomethyl level, the
activities of the C-8-F derivatives decreased. Collectively, these
data establish that the nature of the C-8 moiety influences the
bacteriostatic effect of C-7-ring alkyl groups. Additional exper-
iments are now required to attribute specific structures to
effects on drug uptake, efflux, and trapping of gyrase on DNA.
Since the optimal C-7-ring substituents were one and two
methyl groups, we added C-8-Cl and C-8-Br fluoroquinolones
to the series to assess the effect of altering the C-8 moiety. For
the monomethyl series, compounds containing halogens or
a C-8-OMe group exhibited similar effectiveness, which was
about threefold better than that of the compound lacking
a C-8 substituent (Table 2, strain KD1163). In the case of
the dimethyl series, the C-8-OMe derivative was the most
active; compounds with C-8 halogens varied considerably
in activity, and the compound lacking a C-8 group was as ef-
fective as some halogenated compounds. Collectively, these
measurements indicate that fluoroquinolones with a C-8-OMe
group are generally more effective against wild-type M. smeg-
matis than compounds with fluorine or hydrogen at position
C-8 and that they are most potent when a small alkyl group is
attached to the C-7 ring.
Effect of C-8- and C-7-ring substituents on inhibition of
growth of first-step fluoroquinolone-resistant gyrase mutants.
The relationship between fluoroquinolone structure and activ-
ity against resistant gyrA mutants was examined by determining
the MIC99s of the C-8-OMe, C-8-H, and C-8-F fluoroquino-
TABLE 1. Bacterial strains used in the study
M. smegmatis strain Relevant genotypea Source or reference
KD1163 mc2155 (wild type) S. Cole (4)
KD1987 KD1163 gyrA (A91V) 14
KD1991 KD1163 gyrA (D95Y) 14
KD1995 KD1163 gyrA (D95H) 14
KD1998 KD1163 gyrA (D95N) 14
KD1999 KD1163 gyrA (D95A) 14
KD2003 KD1163 gyrA (D95G) 14
KD2008 KD1163 gyrA (G89C) 14
KD2012 KD1163 gyrA (G89A) 14
a Amino acid abbreviations: A, alanine; D, aspartic acid; C, cysteine; H, his-
tidine; G, glycine; N, asparagine; V, valine; and Y, tyrosine. The first letter
represents the wild-type amino acid at the position indicated by the number. The
second letter indicates the identity of the mutant amino acid at that position.
FIG. 1. Fluoroquinolone structures. A structure common to the compounds
tested is shown, with the variable groups marked X, Y, Z, and C8. Identification
numbers for the compounds are listed below the structures. Due to rotation at
the C-7 position, substitutions at the 39 (X) and 59 (Z) positions are identical.
3338 SINDELAR ET AL. ANTIMICROB. AGENTS CHEMOTHER.
lones for eight mutants of M. smegmatis (Table 2, strains la-
beled as GyrA amino acid changes). The C-8-OMe compounds
were the most effective, followed by the C-8-F derivatives (see
averages for GyrA variants at the bottom of Table 2). Within
the C-8-OMe series, the C-7-ring monomethyl derivative was
generally the most effective; for both the C-8-F and C-8-H
series, the monomethyl compound was optimal about as often
as the dimethyl derivative was. Compounds with large alkyl
groups on the C-7 ring were generally least effective.
The GyrA G89C variant and several substitutions at position
95 were associated with greater resistance than that for the
other variants examined (summarized in Table 3). A compar-
ison of two C-7-ring ethyl compounds showed that the position
of the C-7-ring alkyl affects the identity and susceptibility of the
most resistant variant, particularly when there is a methoxy or
fluorine attached to the C-8 position: for the N-ethyl com-
pounds, the G89C amino acid change was associated with the
most resistance; for the C-39-ethyl derivatives, the D95 substi-
tutions were associated with resistance similar to or greater
than that for the G89C alteration (Table 3). When the mutants
were compared for the effects of the position of the piperazinyl
ring ethyl by determination of the MIC ratio (Table 4), the
G89C variant was distinctly less susceptible than the A91V and
D95 mutants to the N-linked ethyl compounds, at least when a
methoxy or fluorine substituent was attached to the C-8 posi-
tion. In other work we found that GyrA G89C variants are
preferentially selected by high concentrations of the C-7-ring
N-ethyl compound, while D95G variants are selected by the
C-39-ethyl derivative (14), consistent with the data in Tables 3
and 4. The N-isopropyl group also preferentially lowered the
activity against the G89C GyrA variant (Table 4). If we assume
that comparisons among gyrase mutants reflect differences in
intracellular quinolone binding to gyrase, these data indicate
that N-linked alkyl groups interfere with fluoroquinolone
binding to a GyrA protein that contains a Cys-89 mutation,
particularly when a methoxy or halogen is attached to the C-8
position.
Interference between Cys-89 and the N-alkylated C-7 piper-
azinyl ring can be explained by the fluoroquinolone orientation
on a-helix 4 of the GyrA breakage-rejoining fragment. From
X-ray crystallography of the Escherichia coli GyrA protein it
has been argued that a-helix 4 is located on the surface of the
protein, where it interacts with DNA (10). Amino acid se-
quence similarities between the GyrA proteins of E. coli and
M. smegmatis indicate that amino acids 89, 91, and 95 of the
M. smegmatis GyrA protein reside in a-helix 4. A negative inter-
action between Cys-89 and N-linked C-7-ring alkyls suggests
that the C-7-ring binds to gyrase near amino acid 89, while the
remainder of the quinolone interacts with amino acids 91 and
95, the other two positions where strong resistance mutations
map. Such an alignment, which is shown schematically in Fig.
2, explains why a variant of E. coli with a GyrA G81D variation,
which is equivalent to a position 89 mutation in M. smegmatis,
exhibits resistance to fluoroquinolones but not to nalidixic acid
(3): nalidixic acid lacks the C-7 ring required for interference.
Effects of C-8- and C-7-ring substituents on selection of re-
sistant mutants. When large numbers of cells, on the order of
108 to 1010, were incubated on agar plates containing various flu-
oroquinolone concentrations, colony numbers dropped sharply
in the presence of concentrations slightly above the MIC99. At
higher concentrations a plateau was seen for many compounds,
followed by a second sharp drop at very high concentrations
(Fig. 3). To assess the effect of C-7-ring substituents on the
ability of a C-8-OMe group to suppress selection of resistant
mutants, four C-8-OMe compounds that had similar MIC99s
TABLE 2. Effects of fluoroquinolone C-8- and C-7-ring
substituents on MICs for M. smegmatis
Straina and
C-7-ring alkyl
MIC99 (mg/ml)
C-8-H C-8-OMe C-8-F C-8-Cl C-8-Br
KD1163 (GryA1)
None 0.18 0.14 0.044
Methyl 0.10 0.030 0.036 0.029 0.032
Dimethyl 0.043 0.028 0.049 0.058 0.11
C-39-Ethyl 0.12 0.029 0.068
N-Ethyl 0.11 0.033 0.10
N-Isopropyl 0.16 0.14 0.31
KD2012 (GyrA G89A)
None 0.86 0.18 0.42
Methyl 0.92 0.18 0.24
Dimethyl 0.63 0.18 0.24
C-39-Ethyl 1.0 0.28 0.37
N-Ethyl 1.1 0.37 0.43
N-Isopropyl 1.6 0.85 1.6
KD2008 (GyrA G89C)
None 4.7 0.94 0.94
Methyl 2.6 0.73 1.0
Dimethyl 3.8 0.91 1.2
C-39-Ethyl 3.2 0.65 0.73
N-Ethyl 4.4 2.4 3.2
N-Isopropyl 7.4 7.5 9.6
KD1987 (GyrA A91V)
None 1.7 0.41 0.54
Methyl 1.2 0.23 0.46
Dimethyl 0.98 0.41 0.47
C-39-Ethyl 1.2 0.38 0.53
N-Ethyl 1.7 0.51 0.97
N-Isopropyl 1.5 1.4 2.3
KD1990 (GyrA D95A)
None 1.8 0.31 0.65
Methyl 1.2 0.22 0.47
Dimethyl 0.96 0.28 0.43
C-39-Ethyl 2.6 0.3 0.67
N-Ethyl 1.7 0.41 1.5
N-Isopropyl 1.5 1.2 2.4
KD2003 (GyrA D95G)
None 4.5 0.83 1.3
Methyl 2.8 0.49 1.2
Dimethyl 3.0 0.71 1.2
C-39-Ethyl 3.8 0.65 1.4
N-Ethyl 4.3 1.0 2.6
N-Isopropyl 4.3 3.0 5.3
KD1995 (GyrA D95H)
None 3.5 0.57 1.1
Methyl 2.7 0.46 1.0
Dimethyl 3.6 0.59 0.92
C-39-Ethyl 3.8 0.54 1.2
N-Ethyl 3.2 0.76 2.0
N-Isopropyl 3.6 2.3 3.8
KD1998 (GyrA D95N)
None 4.6 0.81 1.3
Methyl 3.3 0.66 1.3
Dimethyl 3.4 0.93 1.3
C-39-Ethyl 3.6 0.63 1.4
N-Ethyl 4.9 1.2 2.6
N-Isopropyl 4.3 4.1 6.8
KD1991 (GyrA D95Y)
None 4.0 0.61 1.6
Methyl 2.6 0.47 1.1
Dimethyl 2.3 0.51 0.91
C-39-Ethyl 3.8 0.47 1.3
N-Ethyl 3.6 0.81 2.3
N-Isopropyl 4.6 2.4 5.8
Avg for GyrA variants
None 3.2 0.58 0.98
Methyl 2.2 0.43 0.86
Dimethyl 2.3 0.56 0.84
C-39-Ethyl 2.9 0.49 0.96
N-Ethyl 3.1 0.93 2.0
N-Isopropyl 3.6 2.8 4.7
a See footnote a of Table 1 for amino acid abbreviations.
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for wild-type cells were compared (Fig. 3A). Differences
among the four compounds were observed with respect to the
concentration at which the high-concentration drop in recov-
ery occurred: compounds with a C-39-ethyl or monomethyl
substituent on the C-7 ring were the most effective, followed by
the dimethyl and N-ethyl compounds (Fig. 3A). The com-
pound with the lowest MIC99 for wild-type cells, the C-7-ring
dimethyl quinolone, ranked third when compared for the con-
centration at which the second drop occurred. Thus, the MIC
for wild-type cells does not tightly correspond to the ability to
suppress selection of resistant mutants. The N-ethyl compound
ranked fourth, as expected, because the MIC99 of this com-
pound for the most resistant mutants was generally higher than
those for the other mutants examined (Table 3).
To determine whether the effects of the C-7-ring substitu-
ents for which data are shown in Fig. 3A are influenced by the
presence of the C-8-OMe group, we examined a set of com-
pounds that differed from the first series in having either a
C-8-H or a C-8-F moiety rather than a C-8-OMe group. In the
C-8-H series, the variation was wider for MIC99 but narrower
for the concentration at which the high-concentration drop
occurred (Fig. 3B). With the C-8-F series, the MIC99 paral-
leled the concentration at the second sharp drop in mutant
recovery (Fig. 3C). Thus, the group at the C-8 position appears
to influence the relationship between wild-type MIC99 and the
concentration needed to cause the second drop in mutant
recovery.
Two other C-8-OMe compounds, one with a C-7-ring N-iso-
propyl group (PD162282) and one lacking a C-7-ring substitu-
ent (PD135042), had MICs that were fivefold higher than those
discussed above (Table 2, strain KD1163). For this pair, the
compound lacking a C-7-ring alkyl substituent was remarkable
for the absence of a plateau (Fig. 4A). The C-8-H and C-8-F
derivatives of this compound also exhibited little plateau re-
gions (Fig. 4B and C). The addition of an N-isopropyl group to
the C-7 ring lengthened the plateau for the C-8-OMe and
C-8-H compounds (Fig. 4A and B), consistent with the poor
activity of the N-isopropyl compounds against resistant mu-
tants (Table 2). For the C-8-F compounds, an isopropyl group
attached to the C-7 ring simply shifted the mutant recovery
curve to higher concentrations (Fig. 4C). This behavior is cur-
rently unexplained. Collectively, the data in Fig. 4 emphasize
that the C-8 moiety influences the relationship between MIC99
and the concentration associated with the second drop in mu-
tant recovery.
MPC. For comparative purposes, we define MPC as the
concentration at which no colony is recovered when more than
1010 cells are applied to agar plates. MPC can be determined
by agar dilution, as is customary for measurement of MIC,
using concentration increments as fine as necessary. We prefer
to estimate MPC by interpolation, as shown in Fig. 5. The
dashed line in Fig. 5 represents a threshold below which more
than 1010 cells must be applied to agar plates to recover a
single colony. The intersection of the dashed line with the
experimental data is used to estimate the MPC. Table 5 shows
the MPCs of the three sets of fluoroquinolones by using the
TABLE 4. MIC ratios for fluoroquinolones differing in
the C-7-ring ethyl and N-isopropyl groups
GyrA amino
acid substi-
tution
MIC ratio
N-Ethyl/C-39-ethyla with
C-8 substituent of:
N-Isopropyl/no alkylb with
C-8 substituent of:
Methoxy Fluorine Hydrogen Methoxy Fluorine Hydrogen
G89C 3.7 4.3 1.4 8.0 10 1.6
A91V 1.3 1.8 1.3 3.4 4.3 0.88
D95ave
c 1.6 1.9 1.4 4.1 4.1 1.0
a Ratio of MICs of fluoroquinolones differing in the position of the C-7-ring
ethyl group, using the data listed in Table 2.
b Ratio of MICs of fluoroquinolones having a C-7-ring N-isopropyl group
relative to the MIC of the fluoroquinolone lacking a C-7-ring alkyl group, using
the data listed in Table 2.
c The average MIC99 (in micrograms per milliliter) was determined with
D95G, D95H, D95N, and D95Y GyrA variants, as listed in Table 2.
TABLE 3. Effect of fluoroquinolone C-8- and C-7-ring substituents on the identities and susceptibilities of
the most resistant gyrA mutant of M. smegmatis
C-7-ring
group
Most resistant mutanta with C-8 substituent of:
Methoxy Fluorine Hydrogen
None D95G,N; G89C (0.94) D95Y (1.6) D95G,N,Y; G89C (4.7)
Methyl D95N; G89C (0.73) D95G,N (1.3) D95G,N (3.3)
Dimethyl D95N; G89C (0.93) D95G,N; G89C (1.3) D95H,N; G89C (3.8)
C-39-Ethyl D95G,N; G89C (0.65) D95G,H,N,Y (1.4) D95G,H,N,Y (3.8)
N-Ethyl G89C (2.4) G89C (3.2) D95G,N; G89C (4.9)
N-Isopropyl G89C (7.5) G89C (9.6) G89C (7.4)
a Effects of mutations were considered indistinguishable when the difference among MICs was less than 15%. Numbers in parentheses are MIC99s (in micrograms
per milliliter) for the most resistant mutant obtained by use of the data listed in Table 2.
FIG. 2. Orientations of fluoroquinolones and GyrA a-helix 4. a-helix 4,
adapted from the crystal structure of the breakage-reunion domain of the GyrA
protein of E. coli (10), is drawn parallel to the long axis of PD161144. Amino acid
numbers represent positions in the M. smegmatis GyrA protein.
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type of analysis used to obtain the results presented in Fig. 5.
The most potent compounds by this assay were C-8-OMe de-
rivatives with a C-7-ring methyl or ethyl group, provided that
the latter is attached to a ring carbon.
A plot of the MPCs of the C-8-H and C-8-OMe compounds
against the MICs of each compound for the most resistant of
the eight gyrA mutants is shown in Fig. 6A. When we assumed
a linear relationship, the value of r (2) was 0.92. Much more
scatter was evident when the MPC was plotted against the
MIC99 for the wild-type cells (Fig. 6B). In this case r was 0.39.
For the C-8-F compounds, the MPCs correlated well with the
MICs for both mutant and wild-type cells (Fig. 6C and D).
Thus, the MIC for the most resistant mutant correlates well
with the MPC; whether the MICs for wild-type cells also cor-
relate with the MPCs depends on the nature of the moiety at
the C-8 position of the fluoroquinolone. A correlation of the
MPC with the MIC for the mutant is consistent with the second
drop in colony recovery on quinolone-containing agar occur-
ring at the point where the quinolone concentration reaches
FIG. 3. Effect of small C-7-ring alkyls on selection of resistant mutants by
fluoroquinolones. M. smegmatis strain KD1163 was applied to agar plates at the
indicated fluoroquinolone concentrations. Fluoroquinolones contained a C-8-
OMe group (A), a C-8-H group (B), and a C-8-F group (C). Symbols for panel
A: squares, PD138926, C-8-OMe C-7-ring dimethyl; diamonds, PD161144, C-8-
OMe C-7-ring N-ethyl; filled circles, PD161148, C-8-OMe C-7-ring 39-ethyl;
half-filled squares, PD135432, C-8-OMe C-7-ring methyl. Symbols for panel B:
squares, PD158804, C-8-H C-7-ring dimethyl; diamonds, PD160788, C-8-H C-7-
ring N-ethyl; filled circles, PD160793, C-8-H C-7-ring 39-ethyl; half-filled squares,
PD138032, C-8-H C-7-ring methyl. Symbols for panel C, squares, PD125232,
C-8-F C-7-ring dimethyl; half-filled squares, PD125275, C-8-F C-7-ring 39-meth-
yl; diamonds, PD160791, C-8-F C-7-ring N-ethyl; filled circles, PD160792, C-8-F
C-7-ring 39-ethyl. A replicate experiment focusing on the second sharp drop in
colony recovery gave results similar to those shown.
FIG. 4. Effect of C-7-ring isopropyl group on selection of resistant mutants
by fluoroquinolones. M. smegmatis was applied to agar plates containing the
indicated fluoroquinolone concentrations. Fluoroquinolones contained a C-8-
OMe group (A), a C-8-H group (B), and a C-8-F group (C). Symbols for panel
A: filled circles, PD135042, C-8-OMe with no addition to C-7-ring; open circles,
PD162282, C-8-OMe C-7-ring N-isopropyl. Symbols for panel B: filled circles,
ciprofloxacin, C-8-H with no addition to the C-7 ring; open circles, PD161645,
C-8-H C-7-ring N-isopropyl. Symbols for panel C: filled circles, PD117962, C-8-F
with no addition to C-7 ring; open circles, PD162281, C-8-F C-7-ring N-isopro-
pyl. A replicate experiment focusing on the second sharp drop in colony recovery
gave results similar to those shown.
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the MIC for the most resistant mutant. At that point resistance
in a wild-type population would require two concurrent muta-
tions, which for M. smegmatis would occur at a frequency of
10214 to 10216 (single-mutation frequencies were about 1027
to 1028; see the plateau region in Fig. 3 and see reference 14).
Such a double-mutation frequency is orders of magnitude too
low to be detected by the methods used in the present work.
Concluding remarks. The present work expands the initial
description of MPC (6) by showing that differences can be
detected among a set of closely related fluoroquinolones and
by showing that the MPC correlates well with the MIC for the
most resistant, first-step gyrA mutant. Measurement of MIC
and MPC also revealed an unexplained interaction between
C-8 substituents and C-7-ring alkyl groups. To be clinically
useful, the MPC must be below the concentration in serum or
tissue at the site of infection. Thus, use of a combination of
MPC and pharmacokinetic parameters provides a way to com-
pare antibacterial agents for their potential ability to restrict
the selection of resistant mutants. Of the first-line antituber-
culosis agents tested, none has an MPC below the maximum
concentration in serum attained during therapy (7). However,
the MPCs of both PD135432 (gatifloxacin) and moxifloxacin,
another C-8-OMe fluoroquinolone, are below maximum con-
centration in serum attained with doses recommended by the
manufacturers (7). Thus, administration of fluoroquinolones
such that concentrations in serum are above the MPC is fea-
sible with existing compounds. Animal and clinical studies are
now needed to determine whether that will severely restrict the
selective enrichment of resistant mutants.
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